{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:46:50Z","timestamp":1766159210466,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The standard procedure for the diagnosis of prostate carcinoma involves the collection of 10\u201312 systematic biopsies (SBx) from both lobes. MRI-guided targeted biopsies (TBx) from suspicious foci increase the detection rates of clinically significant (cs) PCa. We investigated the extent to which the results of the TBx predicted the tumor board treatment decisions. SBx and TBx were acquired from 150 patients. Risk stratifications and recommendations for interventional therapy (prostatectomy and radiotherapy) or active surveillance were established by interdisciplinary tumor boards. We analyzed how often TBx alone were enough to correctly classify the tumors as well as to indicate interventional therapy and how often the findings of SBx were crucial for therapy decisions. A total of 28\/39 (72%) favorable risk tumors were detected in TBx, of which 11\/26 (42%) very-low-risk tumors were not detected and 8\/13 (62%) low-risk tumors were undergraded. A total of 36\/44 (82%) intermediate-risk PCa were present in TBx, of which 4 (9%) were underdiagnosed as a favorable risk tumor. A total of 12\/13 (92%) high-risk carcinomas were detected and correctly grouped in TBx. The majority of csPCa were identified by the sampling of TBx alone. The tumor size was underestimated in a proportion of ISUP grade 1 tumors. Systematic biopsy sampling is therefore indicated for the next AS follow-up in these cases.<\/jats:p>","DOI":"10.3390\/cancers15153915","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:24:24Z","timestamp":1690881864000},"page":"3915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MRI-Guided Targeted and Systematic Prostate Biopsies as Prognostic Indicators for Prostate Cancer Treatment Decisions"],"prefix":"10.3390","volume":"15","author":[{"given":"Furat","family":"Abd Ali","sequence":"first","affiliation":[{"name":"Bielefeld University, Medical School and University Medical Center OWL, Klinikum Lippe Detmold, Department of Urology, 32756 Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Dietrich","family":"Sievert","sequence":"additional","affiliation":[{"name":"Bielefeld University, Medical School and University Medical Center OWL, Klinikum Lippe Detmold, Department of Urology, 32756 Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Eisenblaetter","sequence":"additional","affiliation":[{"name":"Bielefeld University, Medical School and University Medical Center OWL, Klinikum Lippe Detmold, Department of Diagnostic and Interventional Radiology, 32756 Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Titze","sequence":"additional","affiliation":[{"name":"Bielefeld University, Medical School and University Medical Center OWL, Department of Pathology, Klinikum Lippe Detmold, 32756 Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Hansen","sequence":"additional","affiliation":[{"name":"MVZ for Histology, Cytology and Molecular Diagnostics Trier GmbH, 54296 Trier, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Barth","sequence":"additional","affiliation":[{"name":"University of M\u00fcnster, Gerhard-Domagk-Institute of Pathology, M\u00fcnster University Hospital, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-8929","authenticated-orcid":false,"given":"Ulf","family":"Titze","sequence":"additional","affiliation":[{"name":"Bielefeld University, Medical School and University Medical Center OWL, Department of Pathology, Klinikum Lippe Detmold, 32756 Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/JU.0000000000000346","article-title":"Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication","volume":"202","author":"Gulati","year":"2019","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging\u2014Reporting and Data System: 2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","article-title":"Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review","volume":"175","author":"Eichler","year":"2006","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2214\/AJR.19.21836","article-title":"Prognostic Value of Pretreatment MRI in Patients with Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis","volume":"214","author":"Woo","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","article-title":"Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer","volume":"76","author":"Houlahan","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","article-title":"Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study","volume":"154","author":"Elkhoury","year":"2019","journal-title":"JAMA Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_13","unstructured":"Various Authors (2023, May 12). S3 Guideline Prostate Carcinoma, Long Version 6.0. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakrebs\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics."},{"key":"ref_16","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study","volume":"75","author":"Cornel","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: A systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMc1807507","article-title":"MRI-Targeted Biopsy for Prostate-Cancer Diagnosis","volume":"379","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.juro.2014.01.014","article-title":"Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: A prospective study","volume":"192","author":"Thompson","year":"2014","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5489\/cuaj.11085","article-title":"Pre-treatment risk stratification of prostate cancer patients: A critical review","volume":"6","author":"Rodrigues","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2016.11.028","article-title":"Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer","volume":"72","author":"Anderson","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) <\/=6 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-Grade Prostate Cancer: Time to Stop Calling It Cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamainternmed.2022.7100","article-title":"Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate\u2013Risk Prostate Cancer in the US Between 2010 and 2018","volume":"183","author":"Awamlh","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/aja.aja_29_19","article-title":"Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: Prediction of \u201cregression to the mean\u201d using routine clinical features with correlating biochemical relapse rates","volume":"21","author":"Altok","year":"2019","journal-title":"Asian J. Androl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"434.e17","DOI":"10.1016\/j.urolonc.2021.01.020","article-title":"Tumor size and genomic risk in localized prostate cancer","volume":"39","author":"Gaffney","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/his.13712","article-title":"Defining clinically significant prostate cancer on the basis of pathological findings","volume":"74","author":"Matoso","year":"2019","journal-title":"Histopathology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/ijc.29408","article-title":"The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era","volume":"137","author":"Jahn","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.euo.2020.03.002","article-title":"Intermediate-risk Prostate Cancer: Stratification and Management","volume":"3","author":"Preisser","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/MOU.0000000000000671","article-title":"Active surveillance for intermediate-risk prostate cancer: Yes, but for whom?","volume":"29","author":"Overland","year":"2019","journal-title":"Curr. Opin. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013389","DOI":"10.3389\/fsurg.2022.1013389","article-title":"Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naive and previous negative biopsy patients","volume":"9","author":"Mischinger","year":"2022","journal-title":"Front. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pros.24528","article-title":"Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI-algorithm for lesion detection and classification","volume":"83","author":"Oerther","year":"2023","journal-title":"Prostate"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:23:57Z","timestamp":1760127837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":40,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153915"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153915","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}